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Quality assurance and characterization of
narrowband ultraviolet B devices for use at
home: lessons from the HI-Light Vitiligo Trial
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DEAR EDITOR, Handheld narrowband ultraviolet B (NB-UVB)
devices are available for the treatment of various skin condi-
tions, but their optical radiation omissions are often not thor-
oughly characterized. Following a pilot study1 that identified
potential dosimetry issues, we separately characterized and
quality controlled all devices issued to participants in the main
Home Interventions and Light therapy for the treatment of
Vitiligo Trial (HI-Light Vitiligo Trial; ISRCTN 17160087).2–5
The handheld NB-UVB device used in the HI-Light Vitiligo
Trial was the Dermfix 1000MX unit using a LightTech LTC
9W/G23 tube (Androv Medical, Leatherhead, UK). For the
spectral emission measurements, we used a Bentham DMc150
spectroradiometer (Bentham Instruments, Reading, UK) and
for the irradiance measurements an ILT1700 radiometer and
SED005 UVB detector (International Light Technologies, Pea-
body, MA, USA). The spectroradiometer was calibrated against
a mercury lamp with National Physical Laboratory traceable
spectral emissions for both wavelength and spectral irradiance.
The ILT1700 radiometer and detector were field calibrated
monthly against the spectroradiometer during the study.
The characterization identified the device irradiance mea-
sured at 3 min including a 1-min warm-up, spectral emis-
sions, and the variance of irradiance across an initial sample of
10 devices. The spectral emissions of the devices showed good
agreement with the manufacturer’s specification, with a main
emission at 313 nm and subsidiary peaks at 365 nm, 405 nm
and 435 nm. The device irradiance was measured for 10
devices at the comb tip in the middle of the tube. The mean
(SD) of the 10 measurements was found to be 38 (022)
mW cm2, compared with the manufacturer’s specification of
7 mW cm2. This significant deviation from specification
required an adjustment to the HI-Light trial treatment sched-
ule.6 We also considered the variation in output across the
sample of 10 devices. All fell within our clinically determined
rejection criterion of  20%. Simulation of a 9-month course
of treatment for three vitiligo patches in an individual with
skin type VI was carried out with a number (n) of devices,
and the mean drop in output was 23% (SD 88) after one-
third of the treatment course (n = 6), 29% (SD 67) after
two-thirds (n = 4) and 34% (SD 53) after the full treatment
course (n = 2).
During the trial, quality control checks of all devices prior
to issue to participants determined whether the spectral emis-
sions remained the same as at characterization, whether device
output was within our predetermined range and whether each
device was electrically safe. Devices were tested in batches of
15–25. In total 54 of 425 active devices (13%) were rejected
as having an output outside the criterion of 4 mW cm2 
20%.
The characterization results show the importance of testing
devices prior to determining the treatment schedule in the
trial. The 43% discrepancy between output specification (7
mW cm2) and measured output (4 mW cm2) required
adjustment of the treatment schedule. The drop in output of a
device over time was as expected (Figure 1). In clinical prac-
tice this would simply mean that over time the user would
need to move to a higher step of the treatment schedule in
order to achieve a therapeutic dose.
The fact that one in eight devices was rejected due to their
output lying outside the  20% cutoff shows the importance
of measuring device output. The minimum device irradiance
was 24 mW cm2 and the maximum was 50 mW cm2.
This quality control reduced the variance in treatment expo-
sure attributable to device output and demonstrates the useful-
ness of pretreatment checks. Furthermore, given that these
devices may be purchased by members of the public, the out-
put variation from specification and its variation between
tubes shows the need for clinical and technical supervision,
backed up by robust quality assurance processes, during their
use. No devices were rejected due to spectral emissions or
electrical safety.
The device tests described in this paper require expensive
UV test equipment and scientific and technical expertise to
interpret the results. These staff and equipment are not avail-
able at all hospitals, so it may be necessary to develop special-
ist centres that provide support to several dermatology services
in a regional approach.
Our findings regarding the dosimetry and performance of
handheld NB-UVB units will help to inform the design of
community-based phototherapy services in the future. How-
ever, there are additional considerations regarding such ser-
vices.
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Assessing the validity, responsiveness and
reliability of the Recap measure of eczema
control
DOI: 10.1111/bjd.19709
DEAR EDITOR, Research comparing the effectiveness of different
eczema treatments is limited by inconsistency in both outcomes
assessed and the measures used. Harmonising Outcome Mea-
sures for Eczema recommends a core set of outcomes to be
reported in all trials of eczema treatments.1 Recap of atopic
Figure 1 Mean normalized irradiance (normalized to maximum irradiance) vs. time (hours) for six devices. The SD was approximately  12% of
the normalized value at the start,  15% at 2 h and  18% at 4 h.
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